The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discovery
October 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message to heart, largely leaving pharmaceutical monopolies alone as drug prices have skyrocketed.
IGBA Releases Trade Principles to Foster Trade in Generic and Biosimilar Medicines
GENEVA – 26 June 2019 – The International Generic and Biosimilar medicines Association (IGBA) today released a revised report Trade Principles: Generic and Biosimilar Medicines which addresses how trade agreements can be designed to foster trade in generic and biosimilar medicines and improve access to affordable medicines.
More Articles...
- Committing to Global Health: Balancing Access and Sustainability key to success
- IGBA congratulates health Canada for decision on biologics naming that supports growing global consensus
- Statement on the Passing of Dilip Shah
- Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines Association
